Wealth Watch Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Wealth Watch Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-24	Closed	-$10.9K	–	855
2025 Q4	$10.9K	Sell	24 -8	-25%	-$3.45K	﹤0.01%	411
2025 Q3	$12.5K	Buy	+32	New	+$13.4K	0.01%	374

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Wealth Watch Advisors's VRTX Position: Q1 2026 in Review

Wealth Watch Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q1 2026, closing a stake of 24 shares — an estimated $10.9K sold.

Wealth Watch Advisors first reported a position in VRTX in Q3 2025 and held it in 2 quarters. The position peaked at $12.5K in Q3 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Wealth Watch Advisors reported no remaining Vertex Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Wealth Watch Advisors sold 24 Vertex Pharmaceuticals shares in Q1 2026, an estimated $10.9K.
Wealth Watch Advisors first reported a position in Vertex Pharmaceuticals in Q3 2025 and held it in 2 quarters.
Wealth Watch Advisors's Vertex Pharmaceuticals position peaked at $12.5K in Q3 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Wealth Watch Advisors's 13F filing for Q1 2026, filed 15 May 2026.